INTRA-PERITONEAL METASTASES AND OSTEOPOKILOSIS IN BREAST CANCER PATIENT (CLINICAL OBSERVATION)
I.Y. Galaychuk, O.S. Karashivska, M.M. Drosyk
I. Horbachevsky Ternopil National Medical University of the Ministry of Health of Ukraine, Ternopil, Ukraine
DOI: https://doi.org/10.15407/oncology.2024.01.072
Summary. The publication presents a clinical case of a 6-year (2018-2023) follow-up of a patient with stage IIB estrogen receptor positive/HER-2 negative breast cancer, in whom osteopoikilosis and peritoneal metastases were simultaneously diagnosed during the initial CT examination. Thanks to chemo-hormonal-radiation therapy, it was possible to achieve the first remission of the disease, which lasted three years. Prolongation of the disease was manifested by intraperitoneal recurrence of breast cancer, which was proven morphologically after cytoreductive surgery – panhysterectomy with omentectomy. Subsequent adjuvant cycles of chemotherapy had a short-lived effect. A visceral crisis, as a further progression of the disease, forced a change in the approach to the choice of treatment. Timely determination of sensitivity to cytostatics on the basis of miRNA analysis of the patient’s blood serum allowed to conduct targeted polychemotherapy with the achievement of a complete clinical and visual (CT) response, and to put the disease into a second long-term remission.
Key words: breast cancer, peritoneal metastases, osteopoikilosis, miRNA, polychemotherapy.
References
- Beniey M. Peritoneal metastases from breast cancer: a scoping review. Cureus 2019; 11 (8): e5367. doi: 10.7759/cureus.5367.
- Fuke A, Tabei I, Okamoto T, Takeyama Complete remission from peritoneal metastasis of late recurrent breast cancer by endocrine therapy: a case report. Surg Case Rep 2020; 6: 313. https://doi.org/10.1186/s40792-020-01002-9.
- Mostafa S, Habib MB, Ahmed N, et al. Large ascites in a cirrhotic patient reveal an isolated and late metastasis of ductal breast cancer: a case study. Case Rep Oncol 2023; 16: 585–90. https://doi.org/10.1159/000531835.
- Bertozzi S, Londero AP, Cedolini C, et al. Prevalence, risk factors, and prognosis of peritoneal metastasis from breast cancer. Springer Plus 2015; 4: 688. doi: 1186/s40064-015-1449-x.
- Karsten MM, Ingold-Heppner B, Oesterreich S, et al. Clinical and histological characteristics of peritoneal metastases of invasive lobular breast cancer [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5–9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018; 78 (4 Suppl): P1-01-07. doi: 10.1158/1538-7445.SABCS17-P1-01-07.
- Foster JM, Zhang C, Rehman S, et al. The contemporary management of peritoneal metastasis: A journey from the cold past of treatment futility to a warm present and a bright future. CA Cancer J Clin 2023; 73: 49–71. doi: 10.3322/caac.21749.
- Gao H-F, Zhang J-S, Zhang Q-Z, et al. Peritoneal metastasis after treated with abemaciclib plus fulvestrant for metastatic invasive lobular breast cancer: a case report and review of the literature. Front Endocrinol. 2021; 12: doi:10.3389/fendo.2021.659537.
- Finn RS, Crown JP, Lang I, et al. The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as frst-line treatment of estrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/ TRIO-18): a randomised phase 2 study. Lancet Oncol 2015; 16 (1): 25–35. doi: 10.1016/S1470-2045(14)71159-3.
- McLemore EC, Pockaj BA, Reynolds C, et al. Breast cancer: presentation and intervention in women with gastrointestinal metastasis and carcinomatosis. Ann Surg Oncol 2005; 12 (11): 886–94. doi: 10.1245/ASO.2005.03.030.
- Vierra MA, Morgan RB, Eng OS. Advances in therapeutics for peritoneal metastases from colorectal cancer: a narrative review. Dig Med Res 2022; 5: https://dx.doi.org/10.21037/dmr-21-88.
- Sefidbakht S, Ashouri-Taziani Y, Hoseini S, et al. Osteopoikilosis: a sign mimicking skeletal metastases in a cancer patient. Middle East Journal of Cancer 2011; 2 (1): 37–41.
- McArdle A, O’Riordan C, Connolly EM. Osteopoikilosis masquerading as osseous metastases in breast cancer. Breast Cancer 2014; 21: 765–8. https://doi.org/10.1007/s12282-011-0300-7.
- Tin AW, Hardman J, Naisby G. Two cases of mimics of bone metastasis in breast cancer. BJR Case Rep 2017; 4 (2): doi: 10.1259/bjrcr.20170091.
- Benvenuti C, Gaudio M, Jacobs F, et al. Clinical Review on the Management of Breast Cancer Visceral Crisis. Biomedicines 2023, 11, 1083. https://doi.org/10.3390/biomedicines11041083.
- Cardoso F, Paluch-Shimon S, Senkus E, et al. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020, 31: 1623–49. doi: 1016/j.annonc.2020.09.010.
- Yang R, Lu G, Lv Z, et al. Different treatment regimens in breast cancer visceral crisis: A retrospective cohort study. Front Oncol 2022; 12: doi: 10.3389/fonc.2022.1048781.
- Gennari A, André F, Barrios CH, et al. ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer. Ann Oncol 2021, 32 (12): 1475–95. doi: 10.1016/j.annonc.2021.09.019.
- Sbitti Y, Slimani K, Debbagh A, et al. Visceral crisis means short survival among patients with luminal-А metastatic breast cancer: a retrospective cohort study. World J Oncol 2017. 8 (4): 105–9. doi: 10.14740/wjon1043w.
- McGuire A, Brown JA, Kerin MJ. Metastatic breast cancer: the potential of miRNA for diagnosis and treatment monitoring. Cancer Metastasis Rev 2015; 34 (1): 145–55. doi: 10.1007/s10555-015-9551-7.
- Kim SY, Kawaguchi T, Yan L, et al. Clinical relevance of microRNA expressions in breast cancer validated using the cancer genome atlas (TCGA). Ann Surg Oncol 2017; 24 (10): 2943–9. doi: 10.1245/s10434-017-5984-2.
- Karashivska OS, Galaychuk IY, Nitefor LV, Uglyar TYu. Determination of miRNA expression for selection of the next line of chemotherapy in breast cancer patients. Achievements of Clinical and Experimental Medicine 2023; 3: 98–102. doi: 10.11603/1811-2471.2023.v.i3.13951 (in Ukrainian).
- Lukianova NYu, Borіkun TV, Bazas VM, et al. Circulating microRNAs: prospects of use for early diagnostics and monitoring of tumor process. Oncology 2019; 21 (3): 181–91. doi: 10.32471/oncology.2663-7928.t-21-3-2019-g.8001 (in Ukrainian).
- Chekhun V, Lukianova N, Borikun T, et al. The clinical significance of tumor miR-122,-155,-182, and-200b expression in patients with breast cancer. Science and Innovation 2017; 13 (5): 63–9. doi: 10.15407/scine13.05.063.
No comments » Add comment